134 related articles for article (PubMed ID: 21166384)
1. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer.
Fan Y; Murphy TB; Byrne JC; Brennan L; Fitzpatrick JM; Watson RW
J Proteome Res; 2011 Mar; 10(3):1361-73. PubMed ID: 21166384
[TBL] [Abstract][Full Text] [Related]
2. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.
Byrne JC; Downes MR; O'Donoghue N; O'Keane C; O'Neill A; Fan Y; Fitzpatrick JM; Dunn M; Watson RW
J Proteome Res; 2009 Feb; 8(2):942-57. PubMed ID: 19093873
[TBL] [Abstract][Full Text] [Related]
3. 2D gel electrophoresis and mass spectrometry identification and analysis of proteins.
Meleady P
Methods Mol Biol; 2011; 784():123-37. PubMed ID: 21898217
[TBL] [Abstract][Full Text] [Related]
4. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
5. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker.
Skvortsov S; Schäfer G; Stasyk T; Fuchsberger C; Bonn GK; Bartsch G; Klocker H; Huber LA
J Proteome Res; 2011 Jan; 10(1):259-68. PubMed ID: 20977276
[TBL] [Abstract][Full Text] [Related]
6. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.
Schwamborn K; Gaisa NT; Henkel C
Expert Rev Proteomics; 2010 Dec; 7(6):897-906. PubMed ID: 21142890
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
8. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
9. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers of prostate cancer.
Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for prostate cancer detection.
Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
[TBL] [Abstract][Full Text] [Related]
12. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
Shariat SF; Karam JA; Margulis V; Karakiewicz PI
BJU Int; 2008 Mar; 101(6):675-83. PubMed ID: 17941930
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
14. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
[TBL] [Abstract][Full Text] [Related]
15. Proteomics for the identification of new prostate cancer biomarkers.
Ornstein DK; Tyson DR
Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
[TBL] [Abstract][Full Text] [Related]
16. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
19. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
